NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 67 filers reported holding NURIX THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,216,849 | -15.9% | 1,045,285 | +6.9% | 0.00% | 0.0% |
| Q2 2023 | $9,770,735 | +18.2% | 978,051 | +5.1% | 0.00% | 0.0% |
| Q1 2023 | $8,264,542 | +84077.4% | 930,691 | +4.1% | 0.00% | 0.0% |
| Q4 2022 | $9,818 | -99.9% | 894,216 | +9.5% | 0.00% | -50.0% |
| Q3 2022 | $10,638,000 | +8.6% | 816,462 | +5.6% | 0.00% | +100.0% |
| Q2 2022 | $9,797,000 | +7.2% | 773,294 | +18.5% | 0.00% | 0.0% |
| Q1 2022 | $9,141,000 | -49.2% | 652,494 | +5.0% | 0.00% | -50.0% |
| Q4 2021 | $17,993,000 | -4.8% | 621,547 | -1.5% | 0.00% | -33.3% |
| Q3 2021 | $18,895,000 | +80.4% | 630,698 | +59.8% | 0.00% | +200.0% |
| Q2 2021 | $10,472,000 | +4.1% | 394,757 | +22.0% | 0.00% | -50.0% |
| Q1 2021 | $10,058,000 | +53.6% | 323,520 | +62.4% | 0.00% | +100.0% |
| Q4 2020 | $6,550,000 | +2.0% | 199,233 | +8.3% | 0.00% | 0.0% |
| Q3 2020 | $6,420,000 | – | 183,902 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |